Please assess the completion status of the following clinical trial:

Trial Title: Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Men and women with type 2 diabetes that will need enteral nutrition with carbohydrate content.~* Glycemia \>140mg/dL and \< 400mg/dL at admission on the ward.~* Informed consent (patient or legally authorized representative)~Exclusion criteria:~* Hypersensibility to insulin glargine or glulisine, or any other component of the insulin formulation.~* Use of investigational medications during the last 12 months or use of any investigational insulin preparation during the last 4 months.~* History of diabetic ketoacidosis or hyperosmolar hyperglycaemic state or ketonuria.~* Subjects with conditions that are expected to need surgery or intensive care unit (ICU)admission based on discussions with the treatment team and attending physician.~* Pregnancy.~* Severe hepatic disease or active hepatitis.~* Cardiac failure class III or IV (Classification de la New York Heart Association:NYHA).~* Diagnosed advanced autonomic neuropathy.~* Diagnosed cancer.~* Active infection.~* Current therapy with steroids.~* Patients with recognized or suspected endocrine disorders associated with increased insulin resistance, acromegaly, or hyperthyroidism.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Insulin Glargine + Insulin Glulisine
- 2 (Type: ACTIVE_COMPARATOR): Insulin Glulisine

Based on this trial design, predict the completion outcome and termination type (if applicable).